Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging agent could improve detection of rare cancers

NCT ID NCT07621146

Not yet recruiting Diagnosis Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will compare a new radioactive tracer, 18F-AmBF3TATE, to the standard tracer 68Ga-DOTATATE for PET scans in people with neuroendocrine tumors. The goal is to see if the new tracer is as good or better at finding tumors. About 51 participants will receive both tracers and have their scans compared for accuracy and image quality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-AmBF3TATE (a radioactive tracer for PET scans)
What this could lead to
If successful, this could provide a more accessible or higher-quality imaging option for people with neuroendocrine tumors, potentially improving diagnosis and treatment planning.
What could go wrong
This is a small, early-phase study (51 participants) that only tests imaging accuracy, not treatment outcomes. The new tracer may not prove superior or may have unforeseen limitations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary familial medullary thyroid carcinoma neuroendocrine neoplasm paraganglioma pheochromocytoma pheochromocytoma-paraganglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEDULLARY THYROID CARCINOMA NEUROENDOCRINE TUMORS, NET PHEOCHROMOCYTOMA/PARAGANGLIOMA SSTR-EXPRESSING TUMORS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • BC Cancer Vancouver

    Vancouver, British Columbia, V5Z 4E6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.